Recent Updates
Recently added Catalysts
FMS

Unassociated Document Fresenius Medical Care AG & Co. KGaA Investor News Investor Relations Else-Kr ner-Str. 1 61352 Bad Homburg Germany Contact: Oliver Maier Phone: + 49 6172 609 2601 Fax: + 49 6172 609 2301 E-mail: ir@

Key Takeaway: Fresenius Medical Care AG & Co. KGaA Investor News Investor Relations Else-Kr ner-Str. 1 61352 Bad Homburg Germany Contact: Oliver Maier Phone: + 49 6172 609 2601 Fax: + 49 6172 609 2301 E-mail: ir@fmc-ag.com North America: Terry L. Morris Phone: + 1 800 948 2538 Fax: +

Full Press Release Details

Fresenius Medical Care AG & Co. KGaA
Investor News Investor Relations
Else-Kr ner-Str. 1
61352 Bad Homburg
Germany
Contact:
Oliver Maier
Phone: + 49 6172 609 2601
Fax: + 49 6172 609 2301
E-mail: ir@fmc-ag.com
North America:
Terry L. Morris
Phone: + 1 800 948 2538
Fax: + 1 615 345 5605
E-mail: ir@fmc-ag.com
Internet: www.fmc-ag.com
October 1, 2010
Medical Care successfully upsizes and extends credit agreement
Homburg, Germany - Fresenius Medical Care AG & Co. KGaA (the company or FMC AG & Co. KGaA; Frankfurt
Stock Exchange: FME / New York Stock Exchange: FMS), the world's largest provider of dialysis products and services,
today announced successful completion of the upsizing and extension of its senior secured credit facility. The refinancing of
the revolving facility and Term Loan A was well received with a substantial oversubscription and enabled the company
to upsize these facilities by US$250 million for a total facility of US$2.565 billion. The new agreement was extended
from March 31, 2011, to March 31, 2013, matching the final maturity of the US$1.546 billion Term Loan B. The facilities will
be used for general corporate purposes and working capital needs.
Brosnan, chief financial officer of the company, commented: "We are pleased to have successfully extended our senior
credit agreement which provides continued financial flexibility for the company. The significant interest expressed by our
lenders reflects their confidence in our sustainable financial strength and Fresenius Medical Care's confidence in the
future development."
Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1.89 million individuals worldwide. Through its network of 2,599 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 202,414 patients around the globe. Fresenius Medical Care also is the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME, FME3) and the New York Stock Exchange (FMS, FMS/P).
For more information about Fresenius Medical Care, visit the company's website at www.fmc-ag.com.
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.
Last updated: Oct 1, 2010